Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kewaunee Scientific (KEQU) Cash from Financing Activities (2016 - 2026)

Kewaunee Scientific (KEQU) has 16 years of Cash from Financing Activities data on record, last reported at -$853000.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 73.58% year-over-year to -$853000.0; the TTM value through Oct 2025 reached $8.0 million, up 199.91%, while the annual FY2025 figure was $7.4 million, 345.89% up from the prior year.
  • Cash from Financing Activities reached -$853000.0 in Q4 2025 per KEQU's latest filing, up from -$1.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $14.6 million in Q1 2025 and bottomed at -$4.7 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $1.4 million, with a median of $99000.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: soared 639.31% in 2023, then plummeted 526.53% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $4.8 million in 2021, then plummeted by 103.0% to -$145000.0 in 2022, then skyrocketed by 639.31% to $782000.0 in 2023, then crashed by 512.92% to -$3.2 million in 2024, then surged by 73.58% to -$853000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$853000.0 in Q4 2025, -$1.5 million in Q3 2025, and -$4.3 million in Q2 2025.